From Nasdaq.: 2025-05-28 21:46:00

ORIC Pharmaceuticals Inc. announced positive preliminary data from a Phase 1b trial of ORIC-944 in combination with AR inhibitors for mCRPC patients. The stock closed at $5.97, up 3.29%, with further gains of 18.59%. PSA responses were seen in patients with a 59% PSA50 response rate and a 24% PSA90 response rate. The combination regimens showed a favorable safety profile, with most adverse events classified as Grade 1 or 2. A $125 million private placement financing will extend cash runway into 2027. The financing is set to close on May 29, 2025.

Read more at Nasdaq.: ORIC Reports Promising Efficacy & Safety Data From ORIC-944 Phase 1b Trial In MCRPC; Stock Up